TECHNOLOGY DESCRIPTION
The technology refers to biocompatible, biodegradable, non-toxic, and bioresorbable nanoparticles for the delivery of therapeutic or diagnostic compounds to the heart.
The nanoparticles are characterized by a particular affinity for cardiac cells and can be administered via enteral and parenteral routes.
Being able to encapsulate and/or conjugate one or more therapeutic/diagnostic compounds, the nanoparticles can be used in the pharmaceutical industry for the delivery of therapeutic and/or diagnostic compounds to the heart for the treatment of acute or chronic pathological conditions.
The product of the present invention is also versatile and considered as a platform to be potentially used in other medical fields.
BENEFITS
- Self-assembling and low cost production;
- High biocompatibility, biodegradability and non-toxicity;
- Versatile platform capable of conveying different types of therapeutic and/or diagnostic compounds (eg. nucleic acids, peptides, chemical compounds);
- Particularly akin internalization in cardiac cells;
- Potentially applicable for any use to other cellular districts;
- Compatible with the use of the cell-specific targeting molecules;
LIMITATIONS
Total cardiac selectivity, which the team is currently work on
APPLICATIONS
Heart failure, cardiac arrhythmia, diabetic cardiomyopathy, myocardial infarction, cardiac disease in general
MATERIALS
Readiness Level (TRL)
Patent Grading Report |
Patent Grading ReportThe Grading Patents Report evaluates and grades US patents Sample Buy from Wisdomain |
STATUS
Current status
PCT Application
AVAILABILITY
Available for
Licensing
INVENTOR / TEAM
Catalucci Daniele, Miragoli Michele, Lafisco Michele, Tampieri Anna